AveXis redeploying CDMO gene therapy capacity to support COVID-19 project
The Novartis gene therapy business will contribute its technology and dedicated space at a facility run by CDMO Catalent to help produce a COVID-19 vaccine being developed by Massachusetts-based researchers. Massachusetts Eye and Ear and Massachusetts General Hospital have teamed to develop a va ...
AGC Biologics has expanded its CDMO operations by acquiring a mothballed commercial-scale manufacturing facility from AstraZeneca and says it wil ...
Thermo Fisher will take over operations at CSL’s biomanufacturing site in Lengnau – currently under construction – adding 12,000 L of stain ...
Cell therapy manufacturing costs could be reduced dramatically using immobilized growth factors in culture according to research.
Industry int ...
The viral vector market is highly active, and the interest in production technologies is driven by recent approvals in cell and gene therapy, say ...
Recent Tweets
-
RT @Dan5tanton: Orchard Therapeutics has ceased work on a manufacturing plant in Fremont, California, reduced investment in some th… https://t.co/h0JVi3Ice5
3 weeks ago
-
RT @Dan5tanton: Regeneron says depending on trial data it could be producing hundreds of thousands of doses of an antibody cocktail… https://t.co/36qqAVeC3J
4 weeks ago
-
RT @Dan5tanton: Free #COVID19 report available from Informa Connect, based on the responses of over 600 industry folks : The Respon… https://t.co/Lny93CsPNh
4 weeks ago
-
RT @Dan5tanton: Moderna contracts #CDMO @LonzaGroup to scale up production of mRNA vaccine against #COVID19 as it aims to move into… https://t.co/JMp0AsN1uu
4 weeks ago
Trending
Manufacturing
eBook: Next-Generation Vaccines — COVID-19 Challenges, Opportunities, and Patent Questions
Upstream Processing
Industrialize Your Viral Vector Production in Adherent and Suspension Cell Cultures: Know the Pros and Cons
Manufacturing
Quality By Design for Advanced Therapies: An Informed Route to Enhanced Late-Stage Clinical Success and Empowered Process Flexibility
Upstream Processing
A Rapid, Low-Risk Approach Process Transfer of Biologics from Development to Manufacturing Scale